Dian Diagnostics stated in an institutional survey that the company's AI-related business revenue in 2024 will be approximately 20 million yuan, mainly from the commercial application of auxiliary diagnostic products such as AI pathology and special disease library products. The company invests tens of millions of yuan in the field of AI every year, with a core focus on three major directions: data platform, pathology AI and health management. According to the three-year strategic plan, AI business covers four directions: AI-driven clinical decision support, health management, AI+CRO for pharmaceutical services, as well as data base and regional "smart inspection domain" business. It is expected that in the next three years, AI business revenue will maintain an annual compound growth rate far exceeding 100%.